Gilead Sciences (GILD) Operating Income Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) Operating Income Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.20%
Dec 31, 2025 -5.63%
Sep 30, 2025 10.70%
Jun 30, 2025 23.12%
Mar 31, 2025 -1.41%
Dec 31, 2024 17.54%
Sep 30, 2024 21.08%
Jun 30, 2024 1.70%
Mar 31, 2024 -31.50%
Dec 31, 2023 7.10%
Sep 30, 2023 0.00%
Jun 30, 2023 -6.09%
Mar 31, 2023 -4.56%
Dec 31, 2022 27.42%
Sep 30, 2022 -5.74%
Jun 30, 2022 -13.76%
Mar 31, 2022 -44.58%
Dec 31, 2021 -25.31%
Sep 30, 2021 -2.67%
Jun 30, 2021 -13.12%